|
1
|
Yin P, Wang H, Vos T, Li Y, Liu S, Liu Y,
Liu J, Wang L, Naghavi M, Murray CJ and Zhou M: A subnational
analysis of mortality and prevalence of COPD in China From 1990 to
2013: Findings from the global burden of disease study 2013. Chest.
150:1269–1280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guan WJ, Ran PX and Zhong NS: Prevention
and management of COPD in China: Successes and major challenges.
Lancet Respir Med. 4:428–430. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
COPD Group of Chinese Thoracic Society:
Guidelines for the diagnosis and treatment of chronic obstructive
pulmonary disease (2013 revised edition), . Chin J Tuberculosis
Respiratory Dis. 4:255–264. 2013.(In Chinese).
|
|
4
|
Tunks M and Miller D: Canadian Thoracic
Society recommendations for management of chronic obstructive
pulmonary disease-2008 update-highlights for primary care. Can
Respir J. 15:2192008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jung KS, Park HY, Park SY, Kim SK, Kim YK,
Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, et al: Comparison of
tiotropium plus fluticasone propionate/salmeterol with tiotropium
in COPD: A randomized controlled study. Respir Med. 106:382–389.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farne HA and Cates CJ: Long-acting
beta2-agonist in addition to tiotropium versus either tiotropium or
long-acting beta2-agonist alone for chronic obstructive pulmonary
disease. Cochrane Database Syst Rev: CD008989. 2015. View Article : Google Scholar
|
|
7
|
Hodder R: Tiotropium is superior to
salmeterol in reducing frequency of exacerbations: But the effect
of adding tiotropium to the combination of inhaled corticosteroid
and long-acting β(2)-agonist remains unclear. Evid Based Med.
17:93–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeng LM, Yu XL, Zhang QH, Peng QM, Zhou ZJ
and Han FD: The Efficacy and Safety of Tiotropium Plus
Budesonide/Formoterol Compared with Tiotropium in Chinese Patients
with Chronic Obstructive Pulmonary Disease: A Meta-analysis. Chin
Zhong Guo Hu Xi Yu Wei Zhong Jian Hu Za Zhi. 2:119–126. 2016.(In
Chinese).
|
|
9
|
Zhang WJ, Li H, Liu XH and Chen J: Study
on the clinical efficacy of combined inhalation of
budesonide/formoterol and tiotropium bromide in the treatment of
moderate and severe COPD. Guide China Med. 36:148–149. 2013.
|
|
10
|
Mahler DA and Wells CK: Evaluation of
clinical methods for rating dyspnea. Chest. 93:580–586. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
ATS Committee on Proficiency Standards for
Clinical Pulmonary Function Laboratories, . ATS statement:
Guidelines for the six-minute walk test. Am J Respir Crit Care Med.
166:111–117. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jones PW, Quirk FH, Baveystock CM and
Littlejohns P: A self-complete measure of health status for chronic
airflow limitation. The St. George's respiratory questionnaire. Am
Rev Respir Dis. 145:1321–1327. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kersul AL, Iglesias A, Rios A, Noguera A,
Forteza A, Serra E, Agusti A and Cosio BG: Molecular mechanisms of
inflammation during exacerbations of chronic obstructive pulmonary
disease. Arch Bronconeumol. 47:176–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen YH and Wang C: Breif introduction of
GOLD global strategy for diagnosis, treatment and prevention of
chronic obstructive pulmonary disease (2015 revised edition). Zhong
Guo Yi Xue Qian Yan Za Zhi: Dian Zi Ban. 7:34–39. 2015.(In
Chinese).
|
|
15
|
Bateman ED, Rennard S, Barnes PJ,
Dicpinigaitis PV, Gosens R, Gross NJ, Nadel JA, Pfeifer M, Racké K,
Rabe KF, et al: Alternative mechanisms for tiotropium. Pulm
Pharmacol Ther. 22:533–542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Toumpanakis D, Loverdos K, Tzouda V,
Vassilakopoulou V, Litsiou E, Magkou C, Karavana V, Pieper M and
Vassilakopoulos T: Tiotropium bromide exerts anti-inflammatory
effects during resistive breathing, an experimental model of severe
airway obstruction. Int J Chron Obstruct Pulmon Dis. 12:2207–2220.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tashkin DP: Impact of tiotropium on the
course of moderate-to-very severe chronic obstructive pulmonary
disease: The UPLIFT trial. Expert Rev Respir Med. 4:279–289. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morice AH, Celli B, Kesten S, Lystig T,
Tashkin D and Decramer M: COPD in young patients: A pre-specified
analysis of the four-year trial of tiotropium (UPLIFT). Respir Med.
104:1659–1667. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karner C, Chong J and Poole P: Tiotropium
versus placebo for chronic obstructive pulmonary disease. Cochrane
Database Syst Rev: CD009285. 2012. View Article : Google Scholar
|
|
20
|
Vogelmeier C, Hederer B, Glaab T, Schmidt
H, Rutten-van Molken MP, Beeh KM, Rabe KF and Fabbri LM; POET-COPD
Investigators, : Tiotropium versus salmeterol for the prevention of
exacerbations of COPD. N Engl J Med. 364:1093–1103. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ye Q, Zhang LB, Fan RM, Li JM, Hao Q and
Zhao LY: Curative effect of the combination of Symbicort Turbuhaler
and Tiotropium Bromide in the treatment of severe stable chronic
obstructive pulmonary disease patients. Zhong Hua Fei Bu Ji Bing Za
Zhi: Dian Zi Ban. 7:45–48. 2014.(In Chinese).
|
|
22
|
Cazzola M and Molimard M: The scientific
rationale for combining long-acting beta2-agonists and muscarinic
antagonists in COPD. Pulm Pharmacol Ther. 23:257–267. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peters SP: Tiotropium bromide triple
combination therapy improves lung function and decreases asthma
exacerbations. Evid Based Med. 18:1792013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nielsen R, Kankaanranta H, Bjermer L,
Lange P, Arnetorp S, Hedegaard M, Stenling A and Mittmann N: Cost
effectiveness of adding budesonide/formoterol to tiotropium in COPD
in four Nordic countries. Respir Med. 107:1709–1721. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tricco AC, Strifler L, Veroniki AA, Yazdi
F, Khan PA, Scott A, Ng C, Antony J, Mrklas K, D'Souza J, et al:
Comparative safety and effectiveness of long-acting inhaled agents
for treating chronic obstructive pulmonary disease: A systematic
review and network meta-analysis. BMJ Open. 5:e0091832015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dal Negro RW and Celli BR: Patient related
Outcomes-BODE (PRO-BODE): A composite index incorporating health
utilization resources predicts mortality and economic cost of COPD
in real life. Respir Med. 131:175–178. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li HF, Leng J and Huang W: Observation of
curative effect in group C, D COPD pateints treated by inhalation
of tiotropium bromide combined with budesonide/formoterol. J
Kunming Med Univ. 35:62–65. 2014.
|
|
28
|
Lee SD, Xie CM, Yunus F, Itoh Y, Ling X,
Yu WC and Kiatboonsri S: Efficacy and tolerability of
budesonide/formoterol added to tiotropium compared with tiotropium
alone in patients with severe or very severe COPD: A randomized,
multicentre study in East Asia. Respirology. 21:119–127. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Q, Wang M and Du CJ: Observation of
curative effect in pateints with COPD Complicated with chronic
respiratory failure treated by budesonide/formoterol combined with
tiotropium bromide. Chin Health Stand Manag. 6:108–110. 2015.
|
|
30
|
Aaron SD, Vandemheen KL, Fergusson D,
Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor
A, Sharma S, et al: Tiotropium in combination with placebo,
salmeterol, or fluticasone-salmeterol for treatment of chronic
obstructive pulmonary disease: A randomized trial. Ann Intern Med.
146:545–555. 2007. View Article : Google Scholar : PubMed/NCBI
|
